Rituximab receives "complete review" letter Sept. 19 for expanded non-Hodgkin's lymphoma indication including eight weekly doses per treatment, multiple courses of treatment and treatment of patients with bulky disease. FDA requested inclusion of two safety and efficacy tables in the product package insert. IDEC submitted the supplemental BLA Oct. 29, 1999; Rituxin was approved in 1997 for the treatment of patients with relapsed or refractory, low grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma
You may also be interested in...
Fatal mucocutaneous reactions to Genentech/Idec's Rituxan non-Hodgkin's lymphoma treatment are the subject of a "Dear Healthcare Provider" letter sent to oncologists May 8.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011